Finerenone
Chronic Kidney Disease
Institute of Liver and Biliary Sciences, IndiaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
29 Active assets in the Chronic Kidney Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sodium Ferric Gluconate Watson Pharmaceuticals | Phase 4 | BBB |
Iron(Ii) Sulphate (1:1), Heptahydrate Watson Pharmaceuticals | Phase 4 | BBB |
Semaglutide Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
Clopidogrel Hospital Alemão Oswaldo Cruz | Phase 4 | BB |
Aspirin Hospital Alemão Oswaldo Cruz | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Finerenone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →